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ABSTRACT
The RNA-dependent protein kinase (PKR) is acti-
vated by binding to double-stranded RNA (dsRNA).
Activation of PKR by short-interfering RNAs (siRNAs)
and stimulation of the innate immune response has
been suggested to explain certain off-target effects
in some RNA interference experiments. Here we
show that PKR’s kinase activity is stimulated in vitro
3- to 5-fold by siRNA duplexes with 19 bp and 2 nt
30-overhangs, whereas the maximum activation
observed for poly(I) poly(C) was 17-fold over back-
ground under the same conditions. Directed
hydroxyl radical cleavage experiments indicated
that siRNA duplexes have at least four different
binding sites for PKR’s dsRNA binding motifs
(dsRBMs). The location of these binding sites sug-
gested specific nucleotide positions in the siRNA
sense strand that could be modified with a corre-
sponding loss of PKR binding. Modification at these
sites with N
2-benzyl-20-deoxyguanosine (BndG)
blocked interaction with PKR’s dsRBMs and inhib-
ited activation of PKR by the siRNA. Importantly,
modification of an siRNA duplex that greatly reduced
PKR activation did not prevent the duplex from
lowering mRNA levels of a targeted message by
RNA interference in HeLa cells. Thus, these studies
demonstrate that specific positions in an siRNA can
be rationally modified to prevent interaction with
components of cellular dsRNA-regulated pathways.
INTRODUCTION
The RNA-dependent protein kinase (PKR) is a component of
the interferon antiviral response (1). PKR inhibits translation
initiation through the phosphorylation of the alpha subunit of
the initiation factor eIF2 (eIF2a) (2). However, PKR is syn-
thesized in a latent, inactive form that requires association
with double-stranded RNA (dsRNA) or other activator mole-
cules (3). This activation manifests itself initially by autophos-
phorylation followed by the phosphorylation of protein
substrates (4). In addition to its antiviral role, PKR has effects
on the normal maintenance of cell growth, differentiation in
myogenic cells, apoptosis and signal transduction pathways
that control transcription (5–11). Some of these activities
may arise from PKR phosphorylation of proteins other than
eIF2a, since a number of alternate in vitro substrates have
been reported including IkB, p53, B56a, TAT and histone
(9,12–15).
Human PKR is 62 kDa, consisting of a 20 kDa N-terminal
RNA-binding domain and a C-terminal kinase domain (6,16).
The RNA-binding domain is composed of two dsRNA-
binding motifs (dsRBMs) linked by a stretch of 20 amino
acids (Figure 1). dsRBMs are  70 amino acid segments com-
monly found in dsRNA-binding proteins that do not require
speciﬁc sequences of dsRNA for binding (17–20). These
motifs bind 16 bp of dsRNA via interaction with two different
minor groove sites and phosphodiester contacts across the
intervening major groove (21–24). In addition to RNA bind-
ing, activation of PKR also involves dimerization (25,26).
The binding of an activating RNA ligand is thought to facili-
tate PKR self-association. Importantly, although only  16 bp
of dsRNA is required for binding to PKR, activation of the
enzyme requires a longer duplex region (27,28). It has been
suggested that the length effect arises from the requirement
of an activating RNA ligand to support binding to more
Figure 1. Domain map for the dsRNA-dependent protein kinase, PKR.
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doi:10.1093/nar/gkl464than one PKR dsRBM (29). However, precisely how PKR
assembles on an activating RNA is poorly deﬁned at this
time.
Interestingly, the failure to induce a speciﬁc RNAi effect in
certain cells with long dsRNA molecules can be attributed,
at least in part, to the activation of PKR and the resulting
nonspeciﬁc inhibition in translation (30). To overcome this
obstacle, short-interfering RNAs (siRNAs) are used that
mimic the Dicer products of the natural RNAi pathway
(31). These 19 bp duplex RNAs with 2 nt 30 overhangs
were thought previously to be too short to activate PKR,
since the minimum length of an RNA duplex shown to acti-
vate the enzyme in vitro was 33 bp (27). However, recent
studies have indicated that siRNAs can activate PKR both
in vitro and in cultured cells (32,33). Sledz et al. (32) showed
that this activation occurred with a corresponding stimulation
of JaK-STAT signaling and changes in the expression pat-
terns of a number of interferon-regulated genes. Furthermore,
these effects were diminished in a PKR null cell line. How-
ever, there are conﬂicting reports on the extent to which
activation of PKR speciﬁcally, or other components of the
dsRNA-induced antiviral pathways in general, is the cause
of off-target effects observed in RNAi experiments with
mammalian cells (32,34–36). Furthermore, the activation of
PKR in vitro by RNA duplexes of the length found in siRNAs
(19–21 bp) itself has been called into question recently (37).
In this paper, we describe the PKR activation properties of
both unmodiﬁed and chemically modiﬁed siRNAs. The
unmodiﬁed siRNAs studied in this work are PKR activators,
stimulating autophosphorylation to a level 3- to 5-fold above
background. Directed hydroxyl radical cleavage experiments
were used to deﬁne the binding sites on siRNAs for PKR’s
dsRBMs. Site-speciﬁc modiﬁcation at these locations with
a nucleoside analog that projects steric bulk into the duplex
RNA minor groove prevents activation of PKR. Greater than
80% inhibition of the activation observed with an unmodiﬁed
siRNA can occur with as few as two purine N
2-benzyl modi-
ﬁcations located at speciﬁc positions in the siRNA sense
strand. Furthermore, enhanced phosphorylation of PKR
observed upon transfection of siRNA into human tissue
culture cells is reduced by N
2-benzyl modiﬁcations shown
to block PKR activation in vitro. We present a model for
siRNA activation of PKR that is consistent with these
observations. Importantly, modiﬁcations that inhibit PKR
activation do not prevent the siRNA from causing RNA inter-
ference. These observations indicate that chemical modi-
ﬁcation of the nucleobases found in siRNAs can be used to
prevent the interaction with intracellular dsRNA-binding
proteins without blocking RNA interference.
MATERIALS AND METHODS
Oligonucleotide synthesis
All oligoribonucleotides were synthesized in the DNA/
Peptide core facility of University of Utah using an Applied
Biosystems Model 394 DNA/RNA synthesizer. 2-FdI phos-
phoramidite was purchased from Glen Research Inc, VA.
Substitution with benzylamine on resin-bound 2-FdI oligonu-
cleotide was carried out as described by Allerson et al. (38).
The crude deprotected oligonucleotides were puriﬁed using
denaturing PAGE. The samples were analyzed by negative-
ion electrospray mass spectrometry (ESI/MS) using a quadru-
pole mass spectrometer (Quattro-II; Micromass, Inc.). The
resulting multiple-charge mass spectrum was then processed
into a neutral molecular mass spectrum using MaxEnt soft-
ware (Micromass, Inc.). For the molecular masses of individ-
ual BndG-modiﬁed RNA see Supplementary Table 1.
siRNA duplex formation and purification
Hybridization to form siRNA duplexes was accomplished
by combining 3–6 nmol of sense and antisense strands in
80–100 ml of 10 mM Tris, pH 7.4 and 100 mM NaCl. Sam-
ples were heated to 95 C for 5 min in a dry bath incubator
following which the dry bath block was removed from the
heating unit and allowed to cool to room temperature. The
samples were then electophoresed on a 16% native polyacry-
lamide gel. Samples were visualized by UV shadowing and
hybridization conﬁrmed by comparison with single strand
standards. Duplex RNAs were extracted from the gel via
crushing and then soaking overnight at room temperature in
200 mM NaCl and 0.1 mM EDTA. The resulting solution
was phenol: chloroform extracted, ethanol precipitated, sus-
pended in 10 mM Tris–HCl, pH 7.5 and 50 mM KCl, and
quantiﬁed by UV-visible spectroscopy.
PKR activity assay
To compare difference in activities between siRNA, blunt-
ended siRNA, a 37mer duplex and poly(I) poly(C), a PKR
activity assay was performed under identical condition as
described by Gunnery and Mathews (39) in the presence of
1 mM eIF2a substrate (Figure 2). Vector pET-PKR/lPPase
was obtained by cloning wild-type PKR into pET-lPPase
(16). The resulting expression vector was transformed into
Rosetta 2(DE3) cells (Novagen). Protein co-expression was
induced by 1 mM isopropyl-b-D-thiogalactopyranoside in
Luria–Bertani medium at 37 C for 4 h. PKR puriﬁcation was
performed as described previously (40) replacing the size
exclusion column with a heparin column for the second
puriﬁcation step as follows. Following puriﬁcation with the
Ni-NTA column, the buffer was exchanged with phosphate-
buffered saline. The resulting protein solution was applied
to a heparin HP column (Amersham) pre-equilibrated in
10 mM Na2HPO4, pH 7.0. PKR was eluted using a NaCl gra-
dient. To compare the activity of PKR by different modiﬁed
siRNAs (Figures 6 and 7), we used assay conditions that
gave slightly higher activation above background (200 nM
PKR, 20 mM Tris–HCl, pH 7.5, 10 mM MgCl2,5 0m M
KCl, 2 mM DTT, 100 mM ATP, and 0.34 mCi/ml and
250 mg/ml histone type II-A) (41). The reactions were per-
formed by mixing the selected siRNA duplex with a cocktail
consisting of puriﬁed, dephosphorylated PKR, substrate [either
histone type II-A (Figures 6 and 7) or eIF2a (Figure 2)], and
reaction buffer.
32P-ATP was then added and the reactions
were incubated at 30 Cf o r5m i na n dq u e n c h e dw i t hp r e -
heated (95 C) SDS–PAGE loading buffer. Samples were
heated at 95 C for 5 min and electrophoresed on a 13.5%
SDS–PAGE gel followed by exposure to a storage phosphor
autoradiography screen. Labeled proteins were visualized
using a Typhoon PhosphorImager (Pharmacia) and bands
were quantiﬁed using ImageQuant software.
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cleavage experiments
PKR dsRBD E29C-EDTA Fe and Q120C-EDTA Fe were
prepared and used in directed hydroxyl radical cleavage
experiments as described previously (42,43). All cleavage
experiments were performed with 50-end-labeled RNA.
Quantiﬁcation of the cleavage data was performed using
Image Quant software (Molecular Dynamics). To quantify
the cleavage efﬁciency at each nucleotide, the intensity of
the corresponding band in the lane with modiﬁed protein and
RNA without hydroxyl radical generating reagents (hydrogen
peroxide and sodium ascorbate) was subtracted from the lane
with RNA treated with modiﬁed protein and these reagents.
The length of the line adjacent to the nucleotides represents
the resulting cleavage efﬁciency. The pixel count from the
most efﬁcient cleavage site was quantiﬁed and normalized
to one. All the lines depicting the cleavage efﬁciency were
drawn relative to the most efﬁcient cleavage site. Since all
the lanes in each ﬁgure were run on the same gel, the cleav-
age efﬁciencies can be directly compared for the different
siRNAs.
siRNA-mediated gene knockdown
HeLa cells (8000 cells per well) were reverse-transfected in
96-well plates with 30–100 nM siRNA using 0.4 ml siPORT
NeoFX (Ambion, Austin, TX) per well. The medium was
replaced with fresh culture medium (DMEM supplemented
with fetal bovine serum and penicillin/streptomycin) 24 h
after transfection. The cultures were harvested for mRNA
analysis 48 h after transfection. Total RNA from siRNA-
transfected cells was isolated using the RNAqueous 
MagMAX-96 Total RNA Isolation kit (Ambion). The puriﬁed,
DNase-treated RNA was reverse transcribed with random
decamers using the RETROscript  Kit (Ambion). Gene exp-
ression levels were determined by real-time PCR using
SuperTaq  reagents (Ambion) on the ABI Prism 7900 SDS
(Applied Biosystems, Foster City, CA). The data were col-
lected using primers and a dual-labeled probe speciﬁc for
caspase 2 (Assays-on-Demand; Applied Biosystems). 18S
rRNA was ampliﬁed (forward, 50-ttgactcaacacgggaaacct-30;
reverse, 50-agaaagagctatcaatctgtcaatcct-30;p r o b e ,5 0-VIC-accc-
ggcccggacacgga-NFQ-30) as an internal reference to adjust for
well-to-well variances in amount of starting template. The cor-
rected values were normalized to a sample transfected with the
Silencer  Negative Control #1 siRNA (Ambion).
PKR activation in cultured cells by transfected siRNAs
Human A172 cells (3.3 · 10
5 cells per well) were transfected
with 50 nM siRNAs using oligofectamine (Invitrogen)
according to the manufacturer’s protocol in a 6-well plate.
After 2.5 h, cells were lysed in buffer containing 50 mM Tris,
pH 7.4, 150 mM NaCl, 50 mM NaF, 0.1 mM EDTA, 0.1%
Triton X-100, 10% glycerol, 2 mM orthovanadate, 1 mM
phenylmethylsulfonyl ﬂuoride, 10 mM b-glycerophosphate
and Roche’s complete protease inhibitor cocktail. The lysate
was clariﬁed by centrifugation at 12000 g for 10 min at 4 C.
Identical amounts of protein (50 mg) were resolved by 12%
SDS–PAGE and protein bands were transferred on to a
PVDF membrane. The membrane was subjected to western
blotting with antibodies speciﬁc for phospho-PKR (pThr451)
(Cell Signaling Technology), PKR (Santa Cruz Biotechnology)
and GAPDH (Santa Cruz Biotechnology).
RESULTS
PKR binding to siRNA: kinase activation and directed
hydroxyl radical cleavage
We prepared siRNA duplexes and tested their ability to acti-
vate PKR in in vitro kinase assays. This was carried out using
human PKR expressed in Escherichia coli and dephosphory-
lated with protein phosphatase I, as described previously (41)
Figure 2. siRNA activates PKR. (Upper panel) PKR autophosphorylation as a function of dsRNA concentration. (Lower panel) Quantification of the stimulation
of PKR autophosphorylation as a function of dsRNA concentration. The extent of phosphorylation of PKR was measured by storage phosphor autoradiography
and plotted as the ratio to an unstimulated (no RNA) sample. The concentration of each dsRNA tested from left to right is 20 nM, 200 nM and 2 mM except
poly(I) poly(C), which was tested in the absence ( ) or presence (+)o f1 0mg/ml. This concentration of poly(I) poly(C) resulted in the highest stimulation of
PKR autophosphorylation under these conditions (data not shown).
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Dephosphorylation of activated PKR isolated from bacterial
expression systems generates a form of the enzyme that is
responsive to RNA stimulation of its in vitro kinase activity
(16,37,41,44,45). siRNA duplexes were prepared by chemical
synthesis and puriﬁcation of the sense and antisense
strands followed by hybridization and gel puriﬁcation of the
resulting duplex RNAs. PKR autophosphorylation activity
was then measured as a function of siRNA concentration in
the presence of substrate eIF2a (Figure 2) or histone type
II-A (Figures 6 and 7). A 19 bp siRNA with 2 nt 30 overhangs
targeting human caspase 2 showed a 3-fold increase in
autophosphorylation of PKR compared to a control sample
with no RNA added (Figure 2). PKR substrate phosphoryla-
tion was also enhanced by added siRNA (data not shown).
Maximum activation of PKR was observed at an siRNA con-
centration near 1 mM under these in vitro conditions. A 37 bp
duplex RNA activated PKR 5-fold over background levels
under these same conditions. This duplex exceeds the previ-
ously reported minimum length for PKR activation (33 bp)
and was included as a positive control. In addition, the
well-known PKR activator poly(I) poly(C) was capable of
17-fold stimulation over background at its concentration of
maximum activation (10 mg/ml). Thus, an siRNA duplex is
capable of activating PKR in vitro at levels near that of a
37 bp duplex, but substantially less effectively than the
duplex RNA polymer poly(I) poly(C). When the 30 overhangs
overhangs of the siRNA were removed and a 19 bp blunt-
ended duplex was evaluated, stimulation of PKR autophos-
phorylation was reduced slightly to 2-fold over background
(Figure 2). Stimulation of PKR activity by siRNAs is not
highly dependent on sequence, as similar activation levels
were observed for two additional, unrelated siRNA duplexes
targeting either human papilloma virus E7 protein (HPV-E7)
or green ﬂuorescent protein (GFP) (Figures 6 and 7).
Since PKR binds RNA through its dsRBM-containing
RNA-binding domain, we endeavored to deﬁne the dsRBM-
binding sites present on the siRNA using directed hydroxyl
radical cleavage with EDTA Fe tethered to PKR’s dsRBMs.
Both ends of the HPV-E7 siRNA duplex were extensively
cleaved with PKR RBD E29C-EDTA Fe, (46) which com-
prises both dsRBMs including the intervening linker and
bears the tethered EDTA Fe at amino acid position 29 in
dsRBM I (Figure 3A–C). The cleavage patterns observed
arise from EDTA Fe attached to bound PKR RBD, since
these bands are not observed in control reactions lacking
the reagents necessary to induce hydroxyl radical formation
(Figure 3A and B). Multiple cleavage sites at both ends indi-
cate little orientation preference and more than one binding
register in each orientation. This is consistent with PKR’s
low sequence preference for binding perfectly matched
RNA duplexes. The cleavage pattern was suggestive of four
different binding sites on the siRNA for PKR’s dsRBM I.
A similar pattern was observed with an siRNA targeting
GFP (data not shown).
When the HPV-E7 siRNA was cleaved with PKR RBD
Q120C-EDTA Fe (42), which bears the EDTA Fe at amino
acid position 120 in dsRBM II, the 30 end of the antisense
strand (50 end of the sense strand) was the most efﬁciently
cleaved site (Figure 3A, B and D). This cleavage site for
dsRBM II is closer to the end of the duplex than those
identiﬁed for dsRBM I. Other minor cleavage sites are also
Figure 3. Directed hydroxyl radical cleavage to probe the binding of an siRNA with the PKR RBD. (A) Storage phosphor autoradiogram of a 19% denaturing
polyacrylamide gel separating the RNA cleavage products from the HPV-E7 siRNA duplex with the sense strand 50-end-labeled. Major cleavage sites are
identified with lines and arrows. The lanes had the following reaction conditions as labeled: T, T1 RNAse (G-lane); OH, alkaline hydrolysis; lane 1, RNA with no
added reagents (protein, hydrogen peroxide or sodium ascorbate); lane 2, 8 mM PKR RBD E29C-EDTA Fe (46) in the presence of 0.001% hydrogen peroxide
and 5 mM sodium ascorbate (cleavage reagents); lane 3, 8 mM PKR RBD E29C-EDTA Fe in the absence of 0.001% hydrogen peroxide and 5 mM sodium
ascorbate; lane 4, 10 mM PKR RBD Q120C-EDTA Fe (42) in the presence of 0.001% hydrogen peroxide and 5 mM sodium ascorbate; lane 5, 10 mM PKR RBD
Q120C-EDTA Fe in the absence of 0.001% hydrogen peroxide and 5 mM sodium ascorbate. (B) Conditions are the same as in (A) with antisense strand 50 end-
labeled with the exception that A refers to RNAse A cleavage products (A>C lane) (C) Sites of cleavage on the HPV-E7 siRNA induced by PKR RBD modified
with EDTA Fe at position 29 of dsRBM I. Length of each line is proportional to the extent of cleavage at that nucleotide. (D) Sites of cleavage on the HPV-E7
siRNA induced by PKR RBD modified with EDTA Fe at position 120 of dsRBM II.
Nucleic Acids Research, 2006, Vol. 34, No. 17 4903apparent, including some that appear to overlap with those
observed for dsRBM I.
Directed hydroxyl radical cleavage of modified siRNA
Our laboratory has shown previously that individual dsRBM-
binding sites can be selectively disrupted by site-speciﬁc
steric occlusion of minor groove sites by replacing speciﬁc
purines in the duplex RNA with N
2-benzylguanine (Figure 4)
(47,48). Introduction of this bulky modiﬁcation is advanta-
geous, since single mutations that cause only a change in
sequence typically have minimal effect on dsRBM binding.
Furthermore, replacing purines with N
2-benzylguanine main-
tains base pairing (G Co rG  U) and, thus, does not alter the
overall helical structure of the duplex.
We used the benzyl modiﬁcation strategy to disrupt PKR
dsRBM-binding sites present on the siRNA inferred from
directed hydroxyl radical cleavage patterns (Figure 5). From
our experience, a benzyl group incorporated  8n tf r o mt h e
center of a cleavage pattern generated by the PKR RBD
E29C-EDTA Fe protein blocks binding to that site most efﬁ-
ciently (47). Thus, a benzyl group was introduced at position
9 of the siRNA sense strand to disrupt the complex leading
to cleavage at the extreme 30 end of this strand (50 end of
the antisense strand). This was accomplished via incorporation
of 2-ﬂuoro-20-deoxyinosine into the RNA strand using a com-
mercially available phosphoramidite and subsequent substitu-
tion with benzylamine to generate an oligonucleotide with
the requisite purine N
2-benzyl modiﬁcation (Materials and
Methods) (38). Control experiments indicated that deoxy
substitutions alone at the sites chosen for modiﬁcation have
no effect on PKR activation (data not shown). In addition,
to avoid complications from analyzing cleavage data on the
strand containing benzyl modiﬁcations, we modiﬁed only the
sense strand and present cleavage results only for the unmodi-
ﬁed antisense strand. The introduction of N
2-benzyl-20-
deoxyguanosine (BndG) at position 9 of the sense strand led
to disruption of cleavage at the nucleotides corresponding to
the extreme 50 end of the antisense strand (nt 2–4), with the
cleavage at nt 5–7 unchanged (Figure 5A). This conﬁrmed
that the cleavage observed at this location of the duplex (nt
2–7 of the antisense strand) arises from at least two different
dsRBM–RNA complexes. This was further supported by intro-
duction of BndG at position 6 of the sense strand along with
the position 9 modiﬁcation (Figure 5B). The two BndG modi-
ﬁcations completely absolved the 50 end of the antisense strand
from efﬁcient cleavage by the PKR RBD E29C-EDTA Fe
protein. A BndG modiﬁcation at position 3, in addition to posi-
tions 6 and 9, did not cause an appreciable change in the cleav-
age pattern (Figure 5C). However, the cleavage was altered
when BndG was introduced at position 15 in addition to posi-
tions 6 and 9. A reduction of cleavage efﬁciency at nt 13–15
of the antisense strand was observed, while cleavage of nt
16–19 increased (Figure 5D). Thus, like at the 50 end, it
appeared the cleavage patterns observed at the 30 end of the
antisense strand arise from binding at two different sites.
The ability of the PKR RBD E29C-EDTA Fe protein to
cleave duplexes bearing BndG at multiple positions indicated
that the modiﬁcations do not disrupt the duplex structure, but
only limit the ways in which PKR can bind. To address
directly the effect these modiﬁcations have on duplex stabil-
ity, we measured the thermal melting temperatures (Tm’s) of
unmodiﬁed and certain BndG modiﬁed HPV-E7 siRNAs. The
Tm of the unmodiﬁed HPV-E7 siRNA was measured to be
79.6 C, whereas the duplex bearing BndG at positions 6,
9 and 15 had a Tm ¼ 70.6 C. The duplex with BndG
Figure 4. Introduction of N
2-benzyl-20-deoxyguanosine into duplex RNA occludes the minor groove and disrupts dsRBM-RNA binding.
4904 Nucleic Acids Research, 2006, Vol. 34, No. 17Figure 5. Directed hydroxyl radical cleavage to probe PKR RBD binding of benzyl-modified siRNAs. (A–D) Directed hydroxyl radical cleavage by PKR RBD
E29C-EDTA Fe to probe PKR dsRBM I binding of benzyl-modified siRNAs. Conditions for A, OH, lane 1, lane 2 and lane 3 for (A–D) were identical to the
conditions of A, OH, lane 1, lane 2 and lane 3 for Figure 3B. (A) Cleavage pattern on HPV-E7 siRNA benzylated at position 9 on the sense strand. (B) Cleavage
pattern on HPV-E7 siRNA benzylated at positions 6 and 9 on the sense strand. (C) Cleavage pattern on HPV-E7 siRNA benzylated at positions 3, 6 and 9 on the
sense strand. (D) Cleavage pattern on HPV-E7 siRNA benzylated at positions 6, 9 and 15 on the sense strand. (E) Directed hydroxyl radical cleavage by PKR
RBD Q120C-EDTA Fe to probe PKR dsRBM II binding of benzyl-modified siRNAs. A and OH were RNAse A and alkaline hydrolysis, respectively.
Conditions for lane 1, HPV-E7 siRNA benzylated at position 9 with no added cleavage reagents (protein, hydrogen peroxide or sodium ascorbate); lane 2, same
as lane 4 of Figure 3; lane 3, same as lane 5 for Figure 3; lane 4, HPV-E7 siRNA benzylated at position 6 and 9 with no added cleavage reagents; lane 5, same as
lane 4 of Figure 3; lane 6, same as lane 5 for Figure 3. Asterisk indicates a hyper-reactive nucleotide showing cleavage independent of directed hydroxyl radical
cleavage. The cleavage sites disrupted on the antisense strand are shown in the same color as the benzyl-modified nucleotide on the sense strand that causes the
change.
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These observations are consistent with other results suggest-
ing that a single BndG modiﬁcation leads to an  3 C
decrease in the Tm of an siRNA duplex (Supplementary
Table 2).
When PKR RBD Q120C-EDTA Fe was used to cleave the
modiﬁed siRNAs, we found that BndG modiﬁcation at posi-
tion 9 caused a decrease in cleavage efﬁciency at the 30 end
of the antisense strand (Figure 5E). The effect modiﬁcation
at position 9 has on the dsRBM I-directed and dsRBM
II-directed cleavage suggests a binding site on the siRNA that
can be occupied by either motif with one orientation favored
for dsRBM I (cleavage at 50 end of the antisense strand) and
the other favored for dsRBM II (cleavage at 30 end of the anti-
sense strand). Cleavage observed on the duplex bearing BndG
at position 9 was nearly completely inhibited by an additional
modiﬁcation at position 6 (Figure 5E).
The effect of siRNA modification on PKR activation
To determine the effect of BndG modiﬁcation of the siRNA
on PKR activation, we evaluated the ability of the modiﬁed
siRNAs to stimulate PKR’s kinase activity in vitro
(Figure 6A–D). For the HPV E7 siRNA, activation of PKR
was reduced from a maximum stimulation of over 5-fold to
 3-fold when BndG was introduced at positions 6 and 9 of
the sense strand (Figure 6A and B). When the same siRNA
was additionally modiﬁed at position 3, little further reduc-
tion in PKR activation was observed, although a shift in the
concentration of maximal activation was apparent (Figure 6A
and B). Importantly, when BndG was introduced at positions
6, 9 and 15, an  85% reduction in maximum stimulation
of PKR autophosphorylation was observed compared to
unmodiﬁed siRNA.
An siRNA targeting GFP was also shown to activate PKR
in vitro (Figure 6C and D). We modiﬁed this siRNA with
BndG to determine if the effects on PKR activation observed
for the HPV E7 siRNA would be reproduced for an unrelated
sequence. From the effect of modiﬁcations described above,
the cleavage patterns observed on the various siRNAs and
molecular models for dsRBM binding based on these cleav-
age results (see below), it appeared that modiﬁcation of
nucleotides near positions 6, 9, 11 and 14 of the sense strand
would have the greatest effect on PKR binding. Thus, we also
wished to determine if modiﬁcation at subsets of these critical
nucleotide positions would vary in effect. The BndG modi-
ﬁcation was introduced at two positions in the sense strand
in two different duplexes (9, 11 and 9, 14) (Figure 6C). Inter-
estingly, while double modiﬁcation at positions 9 and 11
reduced PKR activation only by  30%, modiﬁcation at
positions 9 and 14 caused an 85% reduction in activation
(Figure 6D).
RNA interference with siRNAs modified to block
PKR activation
To assess the effect on RNA interference activity caused
by chemical modiﬁcations that decrease PKR activation,
we analyzed the knockdown capability of modiﬁed siRNAs
targeting the human caspase 2 message (Figure 7A). To
decrease the ability of the siRNA to activate PKR, the sense
strand was substituted at critical positions to generate two
different modiﬁed duplexes bearing BndG at 2 (9, 14) or
3 (7, 9, 14) nt positions. Modiﬁcation at positions 9 and 14
caused a large decrease in the maximum PKR activation
( 75%), as expected from results with the GFP siRNA
(Figure 7B). Including the additional BndG at position 7
reduced the activation to near background levels (Figure 7B).
Figure 6. Introduction of BndG in the siRNA sense strand inhibits PKR activation. (A) The positions selected for modification based on the affinity cleavage data
are shown on HPV-E7 siRNA. (B) Activation of PKR by (closed circle) unmodified HPV-E7 siRNA, (inverted closed triangle—6,9) (closed diamond—3,6,9)
(closed triangle—6,9,15) modified HPV-E7 siRNA and (closed square) HPV-E7 sense single strand. (C) Positions of nucleotides replaced by BndG are shown
for GFP siRNA. (D) Activation of PKR by (closed square) unmodified GFP siRNA and (closed diamond—9,11) (closed triangle—9,14) modified GFP siRNA
and (closed circle) GFP sense single strand.
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culture cells (A172) transfected with unmodiﬁed caspase 2
siRNA and caspase 2 siRNA modiﬁed at positions 7, 9 and
14 (Figure 7C). The unmodiﬁed caspase 2 siRNA caused an
increase in the phosphoryation of PKR at a critical activation
loop threonine (T451) in comparison to a mock transfection
with oligofectamine alone. Importantly, benzyl modiﬁcation
of the siRNA reduced the level of siRNA-stimulated PKR
phosphorylation observed in these cells (Figure 7C).
The effect unmodiﬁed and BndG-modiﬁed siRNAs have
on caspase 2 mRNA levels was monitored in HeLa cells 48h
post transfection using real time RT–PCR (Figure 7D). The
results were normalized to a scrambled sequence control
siRNA. Unmodiﬁed caspase 2 siRNA reduced message levels
by 80% at all three concentrations tested (10, 30 and 100 nM),
whereas the antisense single strand alone had no effect.
Importantly, the siRNA modiﬁed with BndG at positions 9
and 14 was nearly as effective as unmodiﬁed siRNA at these
concentrations. Furthermore, the siRNA BndG-modiﬁed at
positions 7, 9 and 14, which is an extremely poor activator
of PKR, was capable of reducing caspase 2 message levels
by 70% at 100 nM. However, some potency is lost for this
modiﬁed siRNA, since only  45% knockdown is observed
at 10 nM.
DISCUSSION
In this study, we set out to determine if two processes that
involve the recognition of short dsRNAs (RNA activation
Figure 7. siRNAs modified to block PKR activation are capable of inducing RNA interference. (A) Nucleotides of the caspase 2 siRNA substituted by BndG. (B)
Activation of PKR by (closed circle) unmodified caspase 2 siRNA, (closed diamond—9,14) (closed triangle—7,9,14) modified caspase 2 siRNA and (closed
square) caspase 2 antisense single strand. (C) (Left) Western blot of cell lysate from A172 cells transfected with 50 nM caspase 2 siRNA. (Right) Quantification
of western blot analysis of PKR phosphorylation in response to siRNA transfection. PKR T451 phosphorylation is plotted as an increase above background
(mock transfection) in arbitrary units (mean ± SD for three independent experiments). (D) Caspase 2 message levels in HeLa cells transfected with varying
concentrations of siRNAs. Concentration of each siRNA from left to right were 10, 30 and 100 nM.
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structural requirements in the duplex. Our laboratory has
developed methods for identifying binding sites for dsRBM
proteins on duplex RNA and selectively blocking those
sites by site-speciﬁc chemical modiﬁcation (47,48). We
applied this approach to control the manner in which PKR
binds to siRNAs, which were shown to be PKR activators
both in vitro and in cultured cells. Modiﬁed siRNAs with
varying ability to activate PKR were then tested for their abil-
ity to induce an RNA interference effect. Results of these
experiments suggest that the structural requirements for
PKR activation and RNA interference are distinct, since
chemical modiﬁcation can be used to inhibit siRNA activa-
tion of PKR while maintaining the ability of the siRNA to
knock down its RNAi target. These studies have also pro-
vided additional insight into the relationship between RNA
structure and the efﬁcacy of PKR activation.
SiRNAs activate PKR
Williams and co-workers (32) have presented data showing
activation of PKR by siRNAs both in vitro and in cultured
cells. Recently, Zhang et al. (33) also showed that PKR is
activated in N9 cells when transfected with 50 nM siRNA.
Our results are consistent with theirs and show activation
of PKR by three unrelated siRNAs in vitro and by caspase
2 siRNA in cultured human cells. It is highly unlikely that
the activation seen here comes from contaminating longer
dsRNAs, as has been suggested in other studies (49), since
the siRNA duplexes are puriﬁed on native gels before use
and are prepared from gel puriﬁed, chemically synthesized
strands. Furthermore, site-speciﬁc chemical modiﬁcation
that is shown to inhibit PKR binding also inhibits activation
of PKR by these siRNA duplexes. To address the issue of
30 overhangs playing a role in PKR activation, we showed
that the blunt-ended siRNA still activates PKR, but to a
lesser extent. This may be due to the stabilizing effect of
30 overhangs or the 2 nt overhangs might be involved in
the interactions with the PKR dsRBMs. The observation of
activation of PKR by duplexes with only 19 bp appears to
contradict other reports that indicated duplexes shorter than
33 bp cannot activate PKR (27,37). We would argue that
this may simply be a result of our assay conditions that are
optimized to observe activation by the short RNAs. For
instance, our conditions include the use of a low concentra-
tion of PKR (200 nM) to reduce background activity from
RNA-independent PKR dimerization at higher concentrations
(16). Under these conditions, three different siRNAs with 19
bp and 2 nt 30 overhangs were capable of activating PKR’s
kinase activity in a concentration dependent manner display-
ing the well-established bell-shaped curve for dependence on
the concentration of the activator (Figures 2, 6 and 7). To
compare the difference in activation between a 19 bp
siRNA and a duplex that exceeds the previously reported
minimal length required for activation, we generated a
37mer duplex and examined its ability to activate PKR
under identical conditions. The 37mer proved to be <2-fold
more effective in activating PKR compared to a 19 bp
siRNA. However, the duplex RNA polymer poly(I) poly(C)
showed substantially greater activation of PKR under these
conditions (17-fold versus 3-fold). We believe this is related
to its ability to assemble multiple PKR dimers on the same
RNA duplex molecule allowing both RNA-templated dimer
formation and RNA-templated inter-dimer phosphorylation
(see below).
Site-specific modifications inhibit formation of the
kinase-activating PKR RNA complex
Our directed hydroxyl radical cleavage data indicate that
PKR’s dsRBM I can bind an siRNA duplex in at least four
different ways, with two overlapping cleavage patterns
observed at each end of the duplex. By chemical modiﬁcation
at speciﬁc nucleotides within the putative dsRBM I-binding
sites, the efﬁciency of cleavage was reduced in a predictable
manner. Indeed, the benzyl modiﬁcations inhibited the cleav-
age reaction at speciﬁc nucleotides, consistent with inhibition
of binding at distinct sites. If the modiﬁcations caused a glo-
bal change in helical structure, one would expect to see a
nonspeciﬁc decrease in cleavage efﬁciency throughout the
duplex, which was not observed. Furthermore, although the
BndG modiﬁcations do have an effect on the thermal stability
of the siRNA, these effects cannot explain the differences in
activation observed for duplexes of similar stability modiﬁed
at different sites (Figure 6).
Both dsRBM I- and dsRBM II-directed cleavage was
reduced when BndG was substituted at position 6 of the
sense strand (Figure 5). It is difﬁcult to envision how modi-
ﬁcation at position 6 inhibits dsRBM II binding directly to
this site. Rather we assert it is more likely that the dsRBM
II binding is inhibited because benzylation at position 6
blocks dsRBM I binding in a complex that also involves
the covalently linked dsRBM II contacting the RNA. Thus,
it appears that BndG modiﬁcation at positions 6 and 9
could block interaction of dsRBM I and dsRBM II, res-
pectively, from a PKR monomer. We have observed this
type of simultaneous binding by the two dsRBMs to another
PKR ligand that activates the enzyme (42). These observa-
tions are consistent with a previous proposal that activation
requires enough RNA to bind both of PKR’s dsRBMs (29).
Furthermore, given that PKR’s dsRBMs show little sequence
speciﬁcity, a similar complex can be envisioned with PKR’s
dsRBMs bound at the opposite end of the duplex. This com-
plex should be disrupted by modiﬁcation near the base pairs
related by symmetry. These base pairs include positions 11
and 14 of the sense strand. Indeed, we found that combina-
tions of BndG modiﬁcations near positions 6, 9, 11 or 14 in
the sense strand prevent the duplex from activating PKR
(Figures 6 and 7).
It has been shown recently that PKR undergoes dimeriza-
tion at high concentrations in the absence of dsRNA leading
to autophosphorylation and activation of the kinase (16). Oth-
ers had demonstrated that RNA perturbs the PKR monomer/
dimer equilibrium to favor formation of the dimer (50). These
studies indicated that an important role for an activating RNA
is to serve as a scaffold to assemble the PKR dimer at low
concentrations. This explains the bell-shaped curve observed
for the dependence of PKR activity on RNA concentration
(i.e. at higher RNA concentrations the stoichiometry of the
PKR:RNA complex changes from 2:1 to 1:1). Thus, full
activation of the kinase may require enough RNA to bind
both dsRBMs from both monomers of the dimer (51).
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requirements, the size and positioning of dsRBM-binding
sites and the known requirement for dimerization, our
model for activation of PKR by an siRNA is presented in
Figure 8. We suggest that a PKR dimer assembles on the
siRNA with the two dsRBM I components fully bound to
the duplex. In contrast, the dsRBM II components of the
dimer make partial contact to the duplex at opposite ends.
This is consistent with the binding sites revealed by the
hydroxyl radical cleavage experiments. Since a dsRBM
binds 16 bp across one face of the duplex, four motifs can
be accommodated on this relatively short RNA duplex, as
shown in Figure 8A and B. Given the ‘back-to-back’ nature
of the PKR catalytic domain dimer recently solved by
X-ray crystallography, it appears PKR autophosphorylation
occurs in a trans-interdimer fashion (52,53). The binding
mode we suggest allows two monomers to form a dimer at
low PKR concentrations (Figure 8C) that could phosphorylate
another PKR dimer bound to a different siRNA molecule.
The higher activation observed with the RNA duplex polymer
poly(I) poly(C) compared to the siRNAs most likely
arises from its ability to bind more than one PKR dimer
in an orientation that allows for templated inter-dimer
phosphorylation.
Our model for the active complex involving an siRNA
duplex does not include full contact to the RNA for
dsRBM II from each of the two monomers. We estimate
this would require an additional 4–5 bp at each end, resulting
in a duplex RNA length of 27–29 bp, closer to that reported
previously to be the minimal activation length (between 24
and 33 bp). This is consistent with our observation that a
37mer duplex is a slightly more effective PKR activator
(Figure 2). The 37 bp would more easily accommodate all
four dsRBMs of a PKR dimer. The model is also consistent
with the observed effects of modiﬁcation on kinase activa-
tion. Modiﬁcation at positions 9 and 14 of the siRNA sense
strand causes a 75–80% reduction in maximum activation
(Figures 6D and 7B). Interestingly, this arrangement of
modiﬁcations places the benzyl groups in dsRBM-binding
sites on opposite faces of the helix. This is more effective
at inhibition of PKR than positioning the modiﬁcations on
adjacent faces (e.g. positions 9 and 11 or position 6 and 9).
This could be because this arrangement prevents two dsRBMs
from different PKR monomers from coming in proximity in
the complex, since no pair of adjacent dsRBM-binding sites
is unmodiﬁed.
The effect of PKR-inhibiting modifications on
RNA interference
siRNAs must interact with multiple dsRNA-binding proteins
to function in RNAi including proteins that are part of the
RISC loading complex and RISC itself for the antisense
strand (54). Part of the impetus for this study was to deter-
mine if base modiﬁcations could be made to an siRNA that
inhibited PKR activation while maintaining RNA interfer-
ence activity. A similar approach has been described recently
where backbone modiﬁcations of an siRNA were shown to
block RNAi ‘off-target’ effects arising from partial comple-
mentarity between the antisense strand and off-target mes-
sages (55). This requires detailed information on the RNA
structure/activity relationships for both processes to deter-
mine the extent to which these relationships overlap. We
(42) and others (27,28,37,56) have reported on the effect
changes in duplex RNA structure have on PKR binding and
kinase activation. In addition, there is substantial evidence
in the literature that the RNA interference activity of an
siRNA is maintained after extensive modiﬁcation of both
strands, but particularly for modiﬁcations on the sense strand
(57–60). Modiﬁcations that stabilize the siRNA duplex have
had the effect of increasing potency, probably by slowing
nuclease degradation of the component strands during the
experiment (59–61). Multiple BndG modiﬁcations on the
siRNA sense strand are shown here to decrease RNAi
potency (Figure 7D). Since these modiﬁcations also have a
small destabilizing effect on thermal stability of the duplex,
Figure 8. (A–C) Model for siRNA binding and activation of PKR (21,22,53). The model was generated using Swiss-PdbViewer (70) based on directed hydroxyl
radical cleavage data of the PKR dsRBMs on unmodified HPV-E7 siRNA (Figure 3) and the observed effects of BndG modification on PKR binding and
activation (Figures 5–7). Numbers indicate the positions on the siRNA sense strand where BndG modification disrupts PKR interactions.
Nucleic Acids Research, 2006, Vol. 34, No. 17 4909the decreased RNAi potency observed could be a result of
this stability defect (Supplementary Table 2). This would
likely be overcome with additional modiﬁcations designed
to increase duplex stability.
An important outcome of this study is the generation of
siRNA duplexes with varying ability to activate PKR.
These new reagents should prove valuable in deﬁning further
the extent to which PKR is involved in pathways activated by
siRNAs. For instance, it will be informative to evaluate the
effects on both JaK-STAT signaling and the expression levels
of interferon-stimulated genes in various cell lines transfected
with the modiﬁed siRNAs described here (32,34). In addition,
it will be important to deﬁne their effect on the activity of
other cellular components regulated by dsRNA such as
Toll-like receptors, 20,5 0-oligoadenylate synthases, RNA-
editing adenosine deaminases and dsRNA-activated tran-
scription factors (62–68). Indeed, it has been shown recently
that the RNA-editing adenosine deaminase ADAR1, which is
interferon inducible, decreases the efﬁciency of RNAi by
forming a stable cytoplasmic complex with siRNAs (Kd ¼
0.21 nM) (68). This effect may be enhanced in cell lines
expressing higher levels of ADARs (68,69). The BndG
modiﬁed siRNAs described here likely have reduced binding
afﬁnity for ADAR1, since, like PKR, ADAR1 binds dsRNA
via dsRBMs.
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